parecoxib has been researched along with 4-amylcinnamoylanthranilic acid in 1 studies
| Studies (parecoxib) | Trials (parecoxib) | Recent Studies (post-2010) (parecoxib) | Studies (4-amylcinnamoylanthranilic acid) | Trials (4-amylcinnamoylanthranilic acid) | Recent Studies (post-2010) (4-amylcinnamoylanthranilic acid) |
|---|---|---|---|---|---|
| 436 | 186 | 229 | 33 | 0 | 15 |
| Protein | Taxonomy | parecoxib (IC50) | 4-amylcinnamoylanthranilic acid (IC50) |
|---|---|---|---|
| Transient receptor potential cation channel subfamily M member 2 | Homo sapiens (human) | 1.9367 | |
| Transient receptor potential cation channel subfamily M member 8 | Homo sapiens (human) | 3.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heitel, P; Kalinowsky, L; Merk, D; Proschak, E | 1 |
1 review(s) available for parecoxib and 4-amylcinnamoylanthranilic acid
| Article | Year |
|---|---|
Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.
Topics: Animals; Cyclooxygenase Inhibitors; Drug Discovery; Fatty Acids; Humans; Inflammation; Models, Molecular | 2017 |